Armata Pharmaceuticals, INC. (ARMP) — 8-K Filings

8-K Filings (20)

• 8-K Filing — Dec 1, 2025
• Armata Pharmaceuticals Files 8-K — Oct 22, 2025 Risk: low
  Armata Pharmaceuticals, Inc. filed an 8-K on October 22, 2025, reporting on Regulation FD disclosures and financial statements. The company, formerly known as A
• Armata Pharmaceuticals Files 8-K — Sep 11, 2025 Risk: low
  Armata Pharmaceuticals, Inc. filed an 8-K on September 10, 2025, to report under Regulation FD. The filing indicates the company's common stock trades under the
• Armata Pharmaceuticals Files 8-K on Shareholder Vote Matters — Jun 13, 2025 Risk: low
  Armata Pharmaceuticals, Inc. filed an 8-K on June 13, 2025, reporting on matters submitted to a vote of security holders as of June 12, 2025. The filing details
• Armata Pharmaceuticals Files 8-K — May 19, 2025 Risk: medium
  Armata Pharmaceuticals, Inc. filed an 8-K on May 19, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not conta
• Armata Pharmaceuticals Files 8-K — May 1, 2025 Risk: low
  Armata Pharmaceuticals, Inc. filed an 8-K on May 1, 2025, reporting other events and financial statements. The company, formerly known as AmpliPhi Biosciences C
• Merck to Acquire Armata Pharmaceuticals for $1.7B — Apr 2, 2025 Risk: medium
  Armata Pharmaceuticals, Inc. announced on April 2, 2025, that it has entered into a definitive agreement to be acquired by Merck & Co., Inc. for approximately $
• Armata Pharmaceuticals Files 8-K: Material Agreement & Financial Obligation — Mar 12, 2025 Risk: medium
  On March 12, 2025, Armata Pharmaceuticals, Inc. entered into a material definitive agreement and incurred a direct financial obligation. The filing indicates a
• Armata Pharmaceuticals Files 8-K — Dec 19, 2024 Risk: low
  Armata Pharmaceuticals, Inc. filed an 8-K on December 19, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does n
• Armata Pharma Appoints New CMO, Elects Director — Dec 4, 2024 Risk: medium
  Armata Pharmaceuticals, Inc. announced on December 2, 2024, the appointment of Dr. Paul L. Bolte as Chief Medical Officer and the election of Dr. David J. Ebers
• Armata Pharmaceuticals Announces Material Agreement and Officer Changes — Nov 15, 2024 Risk: medium
  Armata Pharmaceuticals, Inc. announced on November 12, 2024, the entry into a material definitive agreement and changes in its board of directors and officer ap
• Armata Pharmaceuticals Files 8-K — Nov 12, 2024 Risk: low
  Armata Pharmaceuticals, Inc. filed an 8-K on November 12, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does n
• Armata Pharmaceuticals Files 8-K on Officer/Director Changes — Oct 3, 2024 Risk: medium
  Armata Pharmaceuticals, Inc. filed an 8-K on October 3, 2024, reporting events as of September 30, 2024. The filing indicates changes related to the departure o
• Armata Pharmaceuticals Announces CMO Departure, Appoints Interim — Sep 26, 2024 Risk: medium
  Armata Pharmaceuticals, Inc. announced on September 22, 2024, the departure of its Chief Medical Officer, Dr. Jonathan R. Peterson. Concurrently, the company ap
• Armata Pharmaceuticals Files 8-K — Aug 26, 2024 Risk: low
  Armata Pharmaceuticals, Inc. filed an 8-K on August 26, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not
• Armata Pharma Reports Officer/Director Changes & Compensation — Aug 15, 2024 Risk: medium
  Armata Pharmaceuticals, Inc. filed an 8-K on August 15, 2024, reporting events as of July 31, 2024. The filing primarily concerns the departure of directors or
• Armata Pharmaceuticals Appoints New CMO, Adds Directors — Jul 25, 2024 Risk: medium
  Armata Pharmaceuticals, Inc. announced on July 22, 2024, the appointment of Dr. Paul L. Bolte as Chief Medical Officer and the election of Dr. Bolte and Ms. Jen
• Armata Pharmaceuticals Reports Shareholder Vote — Jun 14, 2024 Risk: medium
  Armata Pharmaceuticals, Inc. filed an 8-K on June 14, 2024, reporting on a matter submitted to a vote of its security holders on June 12, 2024. The filing does
• Armata Pharmaceuticals Files 8-K — Mar 22, 2024 Risk: low
  Armata Pharmaceuticals, Inc. filed an 8-K on March 22, 2024, reporting on shareholder nominations and financial statements. The company, formerly AmpliPhi Biosc
• Armata Pharmaceuticals Enters Material Agreement, Creates Financial Obligation — Mar 4, 2024 Risk: medium
  Armata Pharmaceuticals, Inc. entered into a material definitive agreement on March 4, 2024, which also created a direct financial obligation for the company. Th

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX